- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04684719
Type O fuldblod og vurdering af alder under præhospitalt genoplivningsforsøg (TOWAR)
Type O fuldblod og vurdering af alder under præhospital genoplivning (TOWAR) forsøg
Open label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to component blood resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize the hemostatic competency of whole blood relative to its age.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- University of Alabama at Birmingham
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40292
- University of Louisville
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- University of Mississippi Medical Center (UMMC)
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267
- University of Cincinatti
-
Cleveland, Ohio, Forenede Stater, 44109
- Metrohealth Systems
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- University of Pittsburgh
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37920
- University of Tennessee Medical Center
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- University of Texas Health Science Center at Houston
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- University of Washington
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
1.) Injured patients at risk of hemorrhagic shock being transported from scene or referral hospital to a participating TOWAR trial site that meet requirements for initiation of blood or blood component transfusion
AND
2A.) Systolic blood pressure ≤ 90mmHg and tachycardia (HR ≥ 108) at scene, at outside hospital or during transport OR
2B.) Systolic blood pressure ≤ 70mmHg at scene, at outside hospital or during transport
Exclusion Criteria:
- Wearing NO TOWAR opt-out bracelet
- Age > 90 or < 18 years of age
- Isolated fall from standing injury mechanism
- Known prisoner or known pregnancy
- Traumatic arrest with > 5 minutes of CPR without return of vital signs
- Brain matter exposed or penetrating brain injury (GSW)
- Isolated drowning or hanging victims
- Objection to study voiced by subject or family member at the scene
- Inability to obtain IV or intraosseous access
- Isolated burns without evidence of traumatic injury
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Whole Blood
Subjects will receive up to two units of whole blood as collected by local blood bank procedures and stored at 1-6 degrees Celsius initiated in the prehospital phase of care. |
low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site |
|
Aktiv komparator: Component transfusion
Subjects will receive prehospital crystalloid infusion or blood component transfusion resuscitation per site standard care for the respective Emergency Medical unit/service. |
crystalloid infusion or blood component transfusion resuscitation |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
30 Day Mortality
Tidsramme: thru 30 days of enrollment
|
All cause mortality within 30 days |
thru 30 days of enrollment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
3-hour Mortality
Tidsramme: Enrollment through 3 hours
|
Death within 3 hours of enrollment |
Enrollment through 3 hours
|
|
6-hour Mortality
Tidsramme: Enrollment through 6 hours
|
Death within 6 hours of enrollment |
Enrollment through 6 hours
|
|
24-hour Mortality
Tidsramme: Enrollment through 24 hours
|
Death within 24 hours of enrollment |
Enrollment through 24 hours
|
|
In-hospital Mortality
Tidsramme: Enrollment through hospital discharge or 30 days
|
Death prior to hospital discharge |
Enrollment through hospital discharge or 30 days
|
|
Blood and Blood Component Transfusion Amount
Tidsramme: Enrollment through 24 hours
|
Number of units of blood or blood component transfused |
Enrollment through 24 hours
|
|
Multiple Organ Failure (MOF)
Tidsramme: Enrollment through 7 days or ICU discharge
|
Organ dysfunction will be evaluated via the Denver Post-injury Multiple Organ Failure Score. Patients who are never admitted to the Intensive Care Unit (ICU) or those with a length of ICU stay of less than 48 hours will be considered to have a Denver score of 0. A summary of the Denver score may be calculated by summing the worst scores of each of the individual systems over the course of the ICU stay. A summary Denver score > 3 will be classified as MOF. |
Enrollment through 7 days or ICU discharge
|
|
Hospital-acquired Pneumonia
Tidsramme: Number of participants who develop pneumonia through 30 days
|
Pneumonia acquired during hospitalization per Center for Disease Control (CDC) criteria |
Number of participants who develop pneumonia through 30 days
|
|
Blood Stream Infection
Tidsramme: Number of participants who develop blood stream infection through 30 days
|
Blood stream infection during hospitalization per CDC criteria |
Number of participants who develop blood stream infection through 30 days
|
|
Acute Respiratory Distress Syndrome (ARDS)
Tidsramme: Number of participants who develop ARDS through 30 days
|
The Berlin definition for mild ARDS (PaO2/FIO2, ≤ 300 mm Hg + timing, imaging and origin criteria) will be utilized as a threshold value to determine the incidence of ARDS and will be further stratified into Moderate (PaO2/FIO2, ≤ 200 mm Hg) and Severe (PaO2/FIO2, ≤ 100 mm Hg). |
Number of participants who develop ARDS through 30 days
|
|
Abnormal International Normalized Ratio (INR)
Tidsramme: Enrollment through 60 minutes
|
Measurement of platelet hemostatic function |
Enrollment through 60 minutes
|
|
Achievement of Hemostasis
Tidsramme: Enrollment through 4 hours
|
Ability to reach nadir transfusion requirement of 1 unit of red blood cells in a 60-minute time period in the first 4 hours following arrival |
Enrollment through 4 hours
|
|
Transfusion Reaction
Tidsramme: Enrollment through 24 hours
|
Any transfusion complication |
Enrollment through 24 hours
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Jason L Sperry, MD, University of Pittsburgh
Publikationer og nyttige links
Generelle publikationer
- Brunskill SJ, Disegna A, Wong H, Fabes J, Desborough MJ, Doree C, Davenport R, Curry N, Stanworth SJ. Blood transfusion strategies for major bleeding in trauma. Cochrane Database Syst Rev. 2025 Apr 24;4(4):CD012635. doi: 10.1002/14651858.CD012635.pub2.
- Meizoso JP, Cotton BA, Lawless RA, Kodadek LM, Lynde JM, Russell N, Gaspich J, Maung A, Anderson C, Reynolds JM, Haines KL, Kasotakis G, Freeman JJ. Whole blood resuscitation for injured patients requiring transfusion: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2024 Sep 1;97(3):460-470. doi: 10.1097/TA.0000000000004327. Epub 2024 Mar 27.
- Sperry JL, Guyette FX, Cotton BA, Luther JF, Utarnachitt RB, Kutcher ME, Daley BJ, Peetz AB, Patel MB, Goodman MD, Claridge JA, Patel N, Harbrecht BG, Hashmi ZG, Zarychanski R, Neal MD, Yazer MH, Martin-Gill C, Vincent LE, Harner AM, Meyer DE, Latimer AJ, Robinson BR, McKnight CL, Hinckley WR, Miller KR, Jansen JO, Martin D, Fox EE, Rosario-Rivera BL, Wisniewski SR; TOWAR Study Group. Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage. N Engl J Med. 2026 Jun 18;394(23):2317-2328. doi: 10.1056/NEJMoa2602167. Epub 2026 May 18.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY20110430
- W81XWH-16-D-0024 (Andet bevillings-/finansieringsnummer: Department of Defense)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
De-identified data may be shared with the funding agency as well as other researchers upon request to the Principal Investigator.
IPD-delingstidsramme
Data will become available after publication of the primary manuscript.
IPD-delingsadgangskriterier
Requests for data will be submitted in writing and reviewed by the Principal Investigator.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .